Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Issue 7 (July 2017)
- Record Type:
- Journal Article
- Title:
- Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Issue 7 (July 2017)
- Main Title:
- Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study
- Authors:
- Zewinger, Stephen
Kleber, Marcus E
Tragante, Vinicius
McCubrey, Raymond O
Schmidt, Amand F
Direk, Kenan
Laufs, Ulrich
Werner, Christian
Koenig, Wolfgang
Rothenbacher, Dietrich
Mons, Ute
Breitling, Lutz P
Brenner, Herrmann
Jennings, Richard T
Petrakis, Ioannis
Triem, Sarah
Klug, Mira
Filips, Alexandra
Blankenberg, Stefan
Waldeyer, Christoph
Sinning, Christoph
Schnabel, Renate B
Lackner, Karl J
Vlachopoulou, Efthymia
Nygård, Ottar
Svingen, Gard Frodahl Tveitevåg
Pedersen, Eva Ringdal
Tell, Grethe S
Sinisalo, Juha
Nieminen, Markku S
Laaksonen, Reijo
Trompet, Stella
Smit, Roelof A J
Sattar, Naveed
Jukema, J Wouter
Groesdonk, Heinrich V
Delgado, Graciela
Stojakovic, Tatjana
Pilbrow, Anna P
Cameron, Vicky A
Richards, A Mark
Doughty, Robert N
Gong, Yan
Cooper-DeHoff, Rhonda
Johnson, Julie
Scholz, Markus
Beutner, Frank
Thiery, Joachim
Smith, J Gustav
Vilmundarson, Ragnar O
McPherson, Ruth
Stewart, Alexandre F R
Cresci, Sharon
Lenzini, Petra A
Spertus, John A
Olivieri, Oliviero
Girelli, Domenico
Martinelli, Nicola I
Leiherer, Andreas
Saely, Christoph H
Drexel, Heinz
Mündlein, Axel
Braund, Peter S
Nelson, Christopher P
Samani, Nilesh J
Kofink, Daniel
Hoefer, Imo E
Pasterkamp, Gerard
Quyyumi, Arshed A
Ko, Yi-An
Hartiala, Jaana A
Allayee, Hooman
Tang, W H Wilson
Hazen, Stanley L
Eriksson, Niclas
Held, Claes
Hagström, Emil
Wallentin, Lars
Åkerblom, Axel
Siegbahn, Agneta
Karp, Igor
Labos, Christopher
Pilote, Louise
Engert, James C
Brophy, James M
Thanassoulis, George
Bogaty, Peter
Szczeklik, Wojciech
Kaczor, Marcin
Sanak, Marek
Virani, Salim S
Ballantyne, Christie M
Lee, Vei-Vei
Boerwinkle, Eric
Holmes, Michael V
Horne, Benjamin D
Hingorani, Aroon
Asselbergs, Folkert W
Patel, Riyaz S
Krämer, Bernhard K
Scharnagl, Hubert
Fliser, Danilo
März, Winfried
Speer, Thimoteus
… (more) - Abstract:
- Summary: Background: Lipoprotein(a) concentrations in plasma are associated with cardiovascular risk in the general population. Whether lipoprotein(a) concentrations or LPA genetic variants predict long-term mortality in patients with established coronary heart disease remains less clear. Methods: We obtained data from 3313 patients with established coronary heart disease in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. We tested associations of tertiles of lipoprotein(a) concentration in plasma and two LPA single-nucleotide polymorphisms ([SNPs] rs10455872 and rs3798220) with all-cause mortality and cardiovascular mortality by Cox regression analysis and with severity of disease by generalised linear modelling, with and without adjustment for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, estimated glomerular filtration rate, LDL-cholesterol concentration, and use of lipid-lowering therapy. Results for plasma lipoprotein(a) concentrations were validated in five independent studies involving 10 195 patients with established coronary heart disease. Results for genetic associations were replicated through large-scale collaborative analysis in the GENIUS-CHD consortium, comprising 106 353 patients with established coronary heart disease and 19 332 deaths in 22 studies or cohorts. Findings: The median follow-up was 9·9 years. Increased severity of coronary heart disease was associated with lipoprotein(a) concentrations in plasma inSummary: Background: Lipoprotein(a) concentrations in plasma are associated with cardiovascular risk in the general population. Whether lipoprotein(a) concentrations or LPA genetic variants predict long-term mortality in patients with established coronary heart disease remains less clear. Methods: We obtained data from 3313 patients with established coronary heart disease in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. We tested associations of tertiles of lipoprotein(a) concentration in plasma and two LPA single-nucleotide polymorphisms ([SNPs] rs10455872 and rs3798220) with all-cause mortality and cardiovascular mortality by Cox regression analysis and with severity of disease by generalised linear modelling, with and without adjustment for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, estimated glomerular filtration rate, LDL-cholesterol concentration, and use of lipid-lowering therapy. Results for plasma lipoprotein(a) concentrations were validated in five independent studies involving 10 195 patients with established coronary heart disease. Results for genetic associations were replicated through large-scale collaborative analysis in the GENIUS-CHD consortium, comprising 106 353 patients with established coronary heart disease and 19 332 deaths in 22 studies or cohorts. Findings: The median follow-up was 9·9 years. Increased severity of coronary heart disease was associated with lipoprotein(a) concentrations in plasma in the highest tertile (adjusted hazard radio [HR] 1·44, 95% CI 1·14–1·83) and the presence of either LPA SNP (1·88, 1·40–2·53). No associations were found in LURIC with all-cause mortality (highest tertile of lipoprotein(a) concentration in plasma 0·95, 0·81–1·11 and either LPA SNP 1·10, 0·92–1·31) or cardiovascular mortality (0·99, 0·81–1·2 and 1·13, 0·90–1·40, respectively) or in the validation studies. Interpretation: In patients with prevalent coronary heart disease, lipoprotein(a) concentrations and genetic variants showed no associations with mortality. We conclude that these variables are not useful risk factors to measure to predict progression to death after coronary heart disease is established. Funding: Seventh Framework Programme for Research and Technical Development (AtheroRemo and RiskyCAD), INTERREG IV Oberrhein Programme, Deutsche Nierenstiftung, Else-Kroener Fresenius Foundation, Deutsche Stiftung für Herzforschung, Deutsche Forschungsgemeinschaft, Saarland University, German Federal Ministry of Education and Research, Willy Robert Pitzer Foundation, and Waldburg-Zeil Clinics Isny. … (more)
- Is Part Of:
- Lancet. Volume 5:Issue 7(2017)
- Journal:
- Lancet
- Issue:
- Volume 5:Issue 7(2017)
- Issue Display:
- Volume 5, Issue 7 (2017)
- Year:
- 2017
- Volume:
- 5
- Issue:
- 7
- Issue Sort Value:
- 2017-0005-0007-0000
- Page Start:
- 534
- Page End:
- 543
- Publication Date:
- 2017-07
- Subjects:
- Diabetes -- Periodicals
Endocrinology -- Periodicals
Endocrine glands -- Diseases -- Periodicals
616.4 - Journal URLs:
- http://www.sciencedirect.com/ ↗
- DOI:
- 10.1016/S2213-8587(17)30096-7 ↗
- Languages:
- English
- ISSNs:
- 2213-8587
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5146.080050
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 14568.xml